AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas

Inclusion Criteria: * Patients must have a confirmed diagnosis of neurofibromatosis 2 by fulfilling National Institute of Health (NIH) criteria or Manchester criteria, or by detection of a causative mutation in the NF2 gene. * Participants must have progressive or symptomatic meningioma. NOTE 1: Histologic confirmation of meningioma is not required in the setting of compatible radiographic appearance, NOTE2: progression is defined as an increase in target meningioma volume ≥ 20% OR ≥ 3 mm during the past 2 years. \-- Subjects must have a target meningioma that is not amenable to surgery due to patient preference or high risk for surgical complications * Participants must be willing and able to undergo regular MRI scans of the brain * Patients must have measurable disease, defined as at least one meningioma ≥ 1.0 ml that can be accurately measured by contrast-enhanced cranial MRI scan, performed within 28 days of study registration. * Prior surgical resection and radiation therapy for the progressive meningioma are not required for study enrollment. * Patients must have received less than 3 prior chemotherapy regimens for progressive meningioma. * Patients receiving dexamethasone must be able to be treated with alternative corticosteroids such as prednisone, prednisolone, or methylprednisolone in the opinion of the treating physician. * Patients must have available an archival paraffin tumor block sufficient to generate at least 20 unstained slides; or, if a paraffin tumor…